These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28552227)

  • 21. Regulatory insight into the European human pluripotent stem cell registry.
    Kurtz A; Stacey G; Kidane L; Seriola A; Stachelscheid H; Veiga A
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):51-5. PubMed ID: 25457963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of three characterization assays reveals ddPCR of LIN28A as the most sensitive for the detection of residual pluripotent stem cells in cellular therapy products.
    Sun J; Yates C; Dingwall S; Ongtengco C; Power D; Gray P; Prowse A
    Cytotherapy; 2024 Nov; 26(11):1374-1381. PubMed ID: 38934983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA regulation of stem cell-based products.
    Fink DW
    Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manufacturing considerations for clinical uses of therapies derived from stem cells.
    Weber DJ
    Methods Enzymol; 2006; 420():410-30. PubMed ID: 17161709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory watch: The target product profile as a tool for regulatory communication: advantageous but underused.
    Tyndall A; Du W; Breder CD
    Nat Rev Drug Discov; 2017 Mar; 16(3):156. PubMed ID: 28209989
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The goals of FDA regulation and the challenges of meeting them.
    Tyler RS
    Health Matrix Clevel; 2013; 22(2):423-31. PubMed ID: 23668096
    [No Abstract]   [Full Text] [Related]  

  • 29. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 34. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.
    Andrews PW; Cavagnaro J; Deans R; Feigal E; Horowitz E; Keating A; Rao M; Turner M; Wilmut I; Yamanaka S
    Nat Biotechnol; 2014 Aug; 32(8):724-6. PubMed ID: 25093882
    [No Abstract]   [Full Text] [Related]  

  • 36. Current and Future Cell Therapy Standards and Guidelines.
    Atkins JW; West K; Kasow KA
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):839-855. PubMed ID: 31466608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA to steer nanotech.
    Fox JL
    Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
    [No Abstract]   [Full Text] [Related]  

  • 38. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.